

Leveraging Atlas Antibodies from Human Protein Atlas for Insights into Precision Medicine in Cancer

March 27, 2025 9am PDT | 12pm EDT | 4pm GMT | 5pm CET

Join us for an insightful webinar featuring two distinguished experts exploring the latest advancements in precision oncology. From cutting-edge antibody-based biomarker discovery to breakthrough digital PCR applications, this session will highlight transformative tools driving innovation in cancer diagnostics and treatment.

Attend this webinar to:

- Discover how Atlas Antibodies from the Human Protein Atlas can accelerate biomarker discovery and precision medicine approaches.
- Learn about MolBoolean, an advanced *in situ* tool for analyzing molecular interactions in oncology research.
- Explore the power of PCR (ddPCR) in clinical research for detecting actionable mutations which can ultimately lead to personalized treatment approaches.

TALK 1

Leveraging Atlas Antibodies from Human Protein Atlas for Insights into Precision Medicine in Cancer

Presented by Eugenia Kuteeva, PhD, Principal Scientist, Atlas Antibodies



A key challenge in cancer research is identifying reliable biomarkers and therapeutic targets that enable personalized treatment strategies. Advanced antibody technologies and comprehensive protein data provide critical tools to address this challenge.

In this session, Dr. Eugenia Kuteeva, Principal Scientist at Atlas Antibodies, will discuss how monoclonal antibodies originating from the Human Protein Atlas can be leveraged to enhance biomarker discovery, therapeutic targeting and patient stratification in precision medicine.

Dr. Kuteeva will also introduce MolBoolean, a novel *in situ* proximity tool developed in collaboration with Uppsala University, which enables researchers to explore molecular interactions and pathways with unprecedented precision.

In her talk, she will:

- Explain how Atlas Antibodies contribute to biomarker identification and precision oncology.
- Demonstrate the application of MolBoolean for studying molecular interactions in cancer research.
- Discuss case studies showcasing the integration of antibody-based tools in biomarker validation and therapeutic development.

TALK 2

Revolutionizing Precision Oncology Research with ddPCR: Unleashing the Future of Cancer Diagnostics

Presented by Trevor Pitcher, PhD, Senior Director, Biodesix



The landscape of precision oncology is rapidly evolving, with ddPCR emerging as a powerful tool for molecular clinical research. This highly sensitive technique powers research focused on accurate detection of actionable mutations, real-time monitoring of treatment response and improved patient management.

In this session, Dr. Trevor Pitcher, Sr. Director of Medical Affairs at Biodesix, will explore how ddPCR is revolutionizing clinical cancer research. He will provide expert insights into this methodology's critical impact at Biodesix and its future applications in oncology.

In his talk, he will:

- Explain the core principles of ddPCR and its role in transforming molecular clinical research.
- Demonstrate how ddPCR drives clinical research focused on rapid identification of actionable mutations to guide personalized therapeutic strategies.
- Highlight how ddPCR supports clinical research that is advancing real-time treatment monitoring, providing dynamic insights to optimize clinical decision-making.